Abstract
Background: Urinary tract infection (UTI) is one of the most common bacterial infections, representing enormous healthcare-cost and morbidity burdens. Though cranberries have long been used to prevent recurrent UTI (r-UTI), extant evidence is inconsistent. Potentials reasons for inconsistency include using different cranberry preparations (juice versus tablet/capsule), heterogenous populations, and outcome definition. Importantly, juice hardly a feasible long-term therapeutic option and there are no meta-analyses specifically examining tablet/capsule form of cranberry. We conducted an updated meta-analysis to address these inconsistencies. Methods: MEDLINE was systematically searched for, i) placebo-controlled clinical trials, ii) restricted to adults, iii) exclusively investigating cranberry extract in tablet/capsule form to prevent r-UTI, and iv) clearly reporting incidence of any of the three outcomes (detailed subsequently) in treatment and placebo groups. Three outcome measures, i.e culture-confirmed UTI, asymptomatic pyuria/bacteriuria, and symptomatic UTI were meta-analyzed separately. Results: 15 RCTs met inclusion criteria. Ten trials reported culture-confirmed UTI, seven reported asymptomatic pyuria/bacteriuria, and 5 trials reported symptomatic but not culture-confirmed UTI as primary outcome, yielding twelve (n=2391 subjects), ten (n=2565 urine cultures), and seven (n=1325 subjects) independent cohorts, respectively. Meta-analysis revealed a 30% reduced risk of culture-confirmed UTI (pooled RR 0.70, 95% CI 0.54, 0.91; I2=59%), 23% reduction in asymptomatic bacteriuria/pyuria (pooled RR 0.77, 95% CI 0.69, 0.86, I2=75%), and 14% reduction in symptomatic UTI (RR 0.86, 95% CI 0.75, 0.98; I2=48%). Excluding low-risk patients and those with neurogenic bladder having indwelling/intermittent catheterization reduced heterogeneity among culture-confirmed UTI trials revealing baseline risk profile of patients is a significant factor contributing to heterogeneity in extant literature. Funnel plot analysis did not reveal significant publication bias. Discussion: Cranberry extract in capsule/tablet form reduces risk of r-UTI in those with a history of r-UTI, but not in those without such history, or those using indwelling or intermittent catheterization. Major limitation of available data was significant heterogeneity, though without evidence of publication bias.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.